Bio-Rad Antibodies’ Post

ATR inhibition is a promising strategy for cancer therapeutics. At Aprea, we are developing ATRN-119, a differentiated macrocyclic and highly selective, potent, oral ATR inhibitor with antitumor activity. Preliminary results of our ongoing first-in-human study of ATRN-119 were presented recently at the ENA conference. Learn more about Aprea’s pipeline: https://lnkd.in/gtx7gTTK #PrecisionOncology #Data #ClinicalTrials 

🚨 Major breakthrough! The FDA has approved Zihera, a groundbreaking cancer-treating antibody developed by Vancouver-based biotech company Zymeworks! 🎉 This approval marks a huge milestone for treating metastatic HER2-positive biliary tract cancer—a rare and deadly form of GI cancer. This game-changing treatment offers hope where chemotherapy has failed, showing significant tumor shrinkage in clinical trials. 🧬💡 We’re celebrating this success and the incredible innovations coming out of Canada’s biotech sector. 🌍👏 Read More: https://lnkd.in/gygUvQw5 #PharmaInnovation #FDAApproval #CancerResearch #Zymeworks #Biotech #TorontoInstituteOfPharmaceuticalTechnology #MedicalBreakthroughs #Her2Positive #HealthTech

Distinguishing between tumor and normal tissue is a major challenge in cancer drug discovery. Tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) serve as crucial markers, but TSAs are rare, and TAAs often appear in healthy tissue, leading to potential cytotoxicity. In 2024, researchers at A2 Biotherapeutics, Inc. developed a Tmod cell therapy that selectively targets tumor cells by recognizing EGFR or HLA-E (common TAAs) while using HLA-A as a blocker to safeguard healthy tissue. Using REmAb® monoclonal antibody sequencing, they identified the amino acid sequence of an HLA-E antibody to create a Tmod construct, which is then expressed in T-cells. Discover the full publication and case study here: https://hubs.li/Q02Y3cFR0 #AntibodyTherapeutics #CellTherapy #AntibodyEngineering #ProteinSequencing

🚨 The Future of Oncology: Next-Gen ADCs are Here! 🧬 Antibody-drug conjugates (ADCs) are entering their golden age, revolutionising cancer treatment by combining targeted therapy with potent cytotoxic drugs. This $12B market is projected to hit $44B by 2029! 🚀 Highlights: 🔬 Advanced payload & linker tech is widening therapeutic windows. 💊 ZAI Lab, Sutro Biopharma, Inc., and ADC Therapeutics are leading innovation. 💡 Beyond cancer: ADCs could tackle autoimmune diseases in the future! #Oncology #ADCTherapeutics #Biotech #CancerCare #Innovation

Did you know? #Therapeutics for #oncology often work for some time until inevitably resistance to the drug develops. The #cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs. Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again. NYSE: KAPA #KairosPharma #CancerTreatment #HealthcareInnovation #BioTech #PharmaTech #BioTechStock #PharmaStock #NYSE

Read the Editorial Commentary on MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations by Edyta Maria Urbanska, Jens Mollerup, and Jan Trøst Jørgensen and recently published in Translational Lung Cancer Research (Open Access): https://lnkd.in/dM5F5KvZ #medicine #pharmaceuticals #oncology #precisionmedicine #biomarkers

At Cortalix we are developing CTX001, a single-domain antibody to target the PDGF beta Receptor (CD140b) in fibrosis and cancer. See why the PDGF beta Receptor is such an interesting novel radiopharmaceutical target.   #PETimaging #TRT #singledomainantibody #nanobody #PDGFR #CD140b

Translational Drug Development (TD2) understands the nuances of Antibody Drug Conjugate (#ADC) development from the "Bench-to-Bedside." DM or email (mkoratich@td2inc.com) if you would like to learn more! #ADC #antibodydrugconjugate #cancertherapeutic #preclinical #regulatoryconsulting #ind #clinicaldevelopment #clinicaltrial #cro

Today, we presented preclinical data demonstrating potential best-in-class properties including potency and selectivity of ORIC-114, our brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. These preclinical findings underscore the potential best-in-class profile of ORIC-114 and build on previously reported clinical data. Read more here: https://bit.ly/3Yl2Lzd

Really enjoyed this review from Tim Yap on all things synthetic lethal in cancer drug discovery - a nice reflection on how target discovery has benefited from the concept, how therapies are progressing in the clinic, but importantly how to maximize the potential of synthetic lethal drug discovery. https://lnkd.in/dj7GivYz